Dr. Pamela Kunz on the Effectiveness of Immunotherapies and Their Promising Future
Pamela Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, talks about the findings of the phase II study of everolimus plus bevacizumab in pNETs, as well as bevacizumab in progressive pNETS.
Pamela Kunz, MD, assistant professor, Division of Oncology, Stanford University School of Medicine, talks about the findings of the phase II study of everolimus plus bevacizumab in pNETs, as well as bevacizumab in progressive pNETS.
Kunz says that the immunotherapy drug has recently shown successful results in lung cancer and melanoma as well, possibly due to their “agnosticism” regarding disease sites. Looking toward the future, Kunz touches on FDA approvals for newer immunotherapies and their effectiveness in diseases like lung cancer, melanoma and pNETs.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
